Vor Biopharma gains 2.3% premarket after telitacicept gMG results

Vor Biopharma shares rose 2.3% to $18.74 premarket after the company said more than 94% of patients treated with telitacicept in a 48-week late-stage study for generalized myasthenia gravis showed at least a five-point improvement; about 42% reached minimal symptoms at some point over 48 weeks.